CRISPR Therapeutics AG (NASDAQ:CRSP) Stock Has Average Price Target of $67.94

Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) have earned a consensus recommendation of “Moderate Buy” from the nineteen brokerages that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, six have given a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $67.94.

A number of equities research analysts recently issued reports on the company. Citigroup restated a “market outperform” rating on shares of CRISPR Therapeutics in a research note on Monday, September 28th. Citizens Jmp reiterated a “market outperform” rating and set a $80.00 target price on shares of CRISPR Therapeutics in a research report on Monday, August 31st. HC Wainwright reiterated a “buy” rating on shares of CRISPR Therapeutics in a research note on Friday. Needham & Company LLC reiterated a “buy” rating and issued a $82.00 target price on shares of CRISPR Therapeutics in a research note on Monday, August 31st. Finally, William Blair raised shares of CRISPR Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 23rd.

Insider Activity

In other CRISPR Therapeutics news, Director Ali Behbahani sold 13,679 shares of the firm’s stock in a transaction on Thursday, September 17th. The shares were sold at an average price of $57.09, for a total value of $780,934.11. Following the completion of the transaction, the director directly owned 16,637 shares of the company’s stock, valued at $949,806.33. This trade represents a 45.12% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, General Counsel James Kasinger sold 1,990 shares of the business’s stock in a transaction on Tuesday, October 6th. The shares were sold at an average price of $60.04, for a total transaction of $119,479.60. Following the transaction, the general counsel owned 94,784 shares of the company’s stock, valued at $5,690,831.36. This trade represents a 2.06% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 26,069 shares of company stock worth $1,526,910. Company insiders own 5.20% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Affinity Asset Advisors LLC purchased a new stake in CRISPR Therapeutics in the first quarter worth approximately $7,136,000. KBC Group NV grew its position in CRISPR Therapeutics by 3,999.9% during the first quarter. KBC Group NV now owns 116,847 shares of the company’s stock valued at $5,558,000 after acquiring an additional 113,997 shares during the last quarter. Shah Wealth Advisors LLC purchased a new position in shares of CRISPR Therapeutics during the second quarter worth approximately $3,767,000. Monashee Investment Management LLC purchased a new position in shares of CRISPR Therapeutics during the first quarter worth approximately $2,378,000. Finally, Quantinno Capital Management LP raised its stake in shares of CRISPR Therapeutics by 613.5% during the first quarter. Quantinno Capital Management LP now owns 47,989 shares of the company’s stock worth $2,283,000 after acquiring an additional 41,263 shares in the last quarter. Institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Stock Performance

Shares of CRISPR Therapeutics stock opened at $53.39 on Friday. The business’s fifty day simple moving average is $55.14 and its 200 day simple moving average is $53.12. The firm has a market capitalization of $5.16 billion, a P/E ratio of -11.22 and a beta of 1.76. CRISPR Therapeutics has a 12 month low of $44.12 and a 12 month high of $78.00. The company has a current ratio of 17.85, a quick ratio of 17.85 and a debt-to-equity ratio of 0.34.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Tuesday, June 30th. The company reported ($0.94) earnings per share for the quarter. CRISPR Therapeutics had a negative net margin of 3,368.72% and a negative return on equity of 24.39%. The company had revenue of $10.18 million for the quarter. As a group, analysts anticipate that CRISPR Therapeutics will post -4.47 EPS for the current year.

Key Stories Impacting CRISPR Therapeutics

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: Analyst price targets remain well above the current trading level. BofA trimmed its target modestly to $81 from $82 while maintaining a Buy rating. Separately, Citi sees approximately 60% upside, although that potential depends on three key developments going as planned. BofA Adjusts Price Target on CRISPR Therapeutics to $81 From $82, Keeps Buy Rating Citi Sees 60% Upside in CRISPR Therapeutics. Here’s What Has to Go Right.
• Positive Sentiment: CRISPR Therapeutics will present late-breaking Phase 1b data for CTX310 at the American Heart Association Scientific Sessions on November 9. The in vivo CRISPR/Cas9 therapy targets ANGPTL3 for severe hypertriglyceridemia, making the presentation a potentially important clinical catalyst. CRISPR Therapeutics to Present Late-Breaking Data at the AHA Scientific Sessions 2026
• Neutral Sentiment: Wall Street’s overall view is Moderate Buy. The consensus target price is $67.94, supported by two Strong Buy, nine Buy, six Hold, and one Sell rating. This indicates generally favorable sentiment, but also meaningful disagreement about the company’s valuation and clinical risk. CRISPR Therapeutics Stock Now Rated Moderate Buy by Wall Street Analysts
• Negative Sentiment: General Counsel James Kasinger sold 1,990 shares for approximately $119,480. The transaction reduced his holdings by 2.06%, which could weigh modestly on sentiment, though he retained 94,784 shares and the sale does not by itself indicate a change in company fundamentals. CRISPR Therapeutics General Counsel Sells Stock

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG (NASDAQ: CRSP) is a biotechnology company focused on developing gene-editing medicines based on CRISPR/Cas9 technology. The company aims to treat serious diseases by precisely modifying genetic material in patients’ cells, with research programs spanning hematology, oncology, autoimmune diseases, and regenerative medicine.

Its lead product, CASGEVY (exagamglogene autotemcel), is a CRISPR/Cas9-based cell therapy developed with Vertex Pharmaceuticals. CASGEVY is approved in multiple markets, including the United States, United Kingdom, and European Union, for certain patients with sickle cell disease and transfusion-dependent beta thalassemia.